SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending as its latest earnings report, featuring a miss on Adjusted EBITDA and controversy over a non-cash tax benefit boosting net income, fuels intense community debate over its accounting practices and the sustainability of its online used car retail model.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash surged after-hours, driven by an optimistic Q1 marketplace GOV outlook that overshadowed a Q4 earnings and revenue miss, leading to a fierce debate among investors about its current valuation and future growth trajectory.

Remitly Global, Inc. engages in the provision of digital financial services for immigrants and their families. The company was founded by Matthew B. Oppenheimer and Joshua Hug on October 3, 2018 and is headquartered in Seattle, WA.

Remitly Global Inc

Remitly Global is trending strongly after delivering better-than-expected Q4 and full-year results, achieving its first full year of GAAP profitability, and providing robust 2026 guidance, driving significant community excitement and trading volume around its growth narrative and strategic advancements in AI and stablecoins.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as geopolitical concerns regarding Iran escalate and the Federal Reserve sends mixed signals on interest rates, fueling intense community debate over potential market manipulation while dip-buying bulls continue to challenge bearish reversal predictions.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending as its strong community actively locks over 40% of the supply through the AirLock mechanism, generating significant discussion around enhanced supply control and its position as a trustworthy Solana meme coin with aspirations for widespread exchange listings.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing a surge in attention following European Commission approval for its Anktiva drug across 33 countries, alongside recent Saudi FDA authorizations, sparking widespread community anticipation for global market expansion and a significant short squeeze against high short interest.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is trending due to its strong Q4 earnings beat, optimistic 2026 guidance, and an announced 25-for-1 stock split coupled with a dividend hike. The community is largely bullish on this comprehensive positive news, though some express reservations about historical stock split performance and potential competitive impacts from AI.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending due to recent analyst upgrades citing strong AI server demand and a reaffirmed long-term dividend growth pledge, while community discussion centers on alleged market manipulation by a prominent investment bank and the potential impact of surging memory prices on upcoming earnings amidst fierce competition in the AI infrastructure sector.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is actively trending following recent contract awards for hypersonics, unmanned systems, and satellite ground segments, including its participation in the significant Drone Dominance Program. The community is keenly anticipating upcoming earnings and discussing its strategic role in a landscape of increasing global defense spending and evolving military technology.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing significant institutional accumulation, highlighted by Cormorant Asset Management's substantial share repurchase, signaling strong confidence in its nanobody pipeline. The community is actively discussing the upcoming Investor Day, anticipating new data for sonelokimab across various inflammatory diseases to reinforce its 'best-in-class' potential and fuel short squeeze and buyout speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours

Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capital as financial advisor amid restructuring and strategic plans. read more...

Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today

QNCX, SPOT, SPGI, INTC, DDOG were among the stocks trending among investors on Tuesday, Feb. 10, 2026.read more...

<ul class="summary-bullets"><li>The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to Quince Therapeutics.</li><li>On January 29, QNCX shares plunged 91.5% after the company said it would halt clinical development of its lead asset Edsp.</li><li>Lucid Capital double-downgraded Quince Therapeutics to ‘Sell’ from ‘Buy’ late last month.</li></ul>Shares of Quince Therapeutics, Inc. (QNCX) surged nearly 60% in pre-market trading on Tuesday after the company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to the company. In addition to assessing these opportunities, LifeSci Capital will advise Quince Therapeutics on any potential restructuring of its liabilities.Quince, a late-stage biotechnology firm focusing on rare disease treatments, added that it will not provide updates during the review and will disclose developments only if its board approves a specific action or deems further communication necessary.<h2 class="st-heading-2">96% Market Value Erased In Just Over A Week</h2>Quince Therapeutics’ stock has been under heavy selling pressure lately. On January 29, QNCX shares plunged 91.5% after the company <a href="https://stocktwits.com/news-articles/markets/equity/qncx-stock-plummets-over-90-percent/cmyipqPR410">said</a> it would halt clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).The late-stage trial in 105 patients with Ataxia-Telangiectasia, a rare and inherited neurodegenerative disorder, did not meet statistical significance for its primary endpoint. The study also missed its key secondary goal. The stock declined a further 37% in the following session.<a href="https://stocktwits.com/symbol/QNCX">QNCX shares</a> have declined nearly 96% from January 28 to Monday’s close.<h2 class="st-heading-2">Wall Street Turns Bearish</h2>The results prompted Lucid Capital to double downgrade Quince Therapeutics to ‘Sell’ from ‘Buy’ with a price target of $0, down from $8. The firm noted that the program, which is Quince’s asset, will be discontinued, and, given that the company’s estimated cash and long-term debt are nearly equal, it sees no value in the shares.The company has also faced mounting financial pressure. In the third quarter of fiscal 2025, Quince reported a net loss of $13.3 million, more than quadrupling the $3.2 million loss from a year earlier. Total operating expenses jumped 130% to $13.4 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/QNCX_jpg_46df9654d8.webp" alt="QNCX.jpg" width="927" height="111"><figcaption>QNCX's Sentiment Meter and Message Volumes at Premarket on Feb. 10, 2026 | Source: Stocktwits</figcaption></figure>One bullish user noted the high volumes in after-market trading.<stembedurl>https://stocktwits.com/Risley/message/644527590</stembedurl>However, one bearish user highlighted the company’s shortcomings in the clinical trial.<stembedurl>https://stocktwits.com/Marceltrade/message/644532523</stembedurl>Over the past year, the stock has slumped 91%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-subdued-tsla-rblx-tsm-hood-kd-stocks-to-watch/cZbUbhPR4Y9">Nasdaq, S&amp;P 500 Futures Subdued After Dow Closes Above 50,000: Why TSLA, RBLX, TSM, HOOD, KD Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout?

The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.

This Nano-Cap Biotech Stock Soars 60% Pre-Market Just Days After A Near-Total Wipeout – Here’s What’s Driving The Move

Equity

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic...

Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease

Quince Therapeutics shares plunged nearly 90% after its Phase 3 trial for a rare genetic disorder missed primary and secondary goals, despite showing no major safety concerns.read more...

Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp

Citizens Jmp cut shares of Quince Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday...

<ul class="summary-bullets"><li>Quince on Thursday announced that the primary endpoint in the late-stage trial evaluating the asset in 105 patients with Ataxia-Telangiectasia did not reach statistical significance.</li><li>The study further did not meet its key secondary endpoint though the therapy was generally well tolerated with no clinically meaningful safety concerns, the company said. &nbsp;</li></ul> Shares of Quince Therapeutics, Inc. (QNCX) closed 92% lower on Thursday after the company said that it has decided to cease clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).Quince <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260129349326/en/Quince-Therapeutics-Announces-Topline-Results-from-Pivotal-Phase-3-NEAT-Clinical-Trial-of-eDSP-in-Ataxia-Telangiectasia">announced</a> that the primary endpoint in the late-stage trial evaluating the asset in 105 patients with Ataxia-Telangiectasia did not reach statistical significance.Moreover, the study did not meet its key secondary endpoint though the therapy was generally well tolerated with no clinically meaningful safety concerns, the company said. &nbsp;<h2 class="st-heading-2">What Is Ataxia-Telangiectasia?</h2>Ataxia-Telangiectasia (A-T) is a rare, inherited neurodegenerative disorder caused by mutations in the ATM gene, leading to progressive loss of coordination, small, visible blood vessels in the eyes/skin, a weakened immune system, and a high risk of cancer, typically appearing in early childhood with unsteady walking and balance issues.Patients with the condition have a median lifespan of approximately 25 to 30 years. There are no approved therapies for the disorder in any global market, as per Quince, though there are about 4,600 diagnosed patients with A-T in the U.S.Shares of the company edged up 2% after hours at the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around QNCX shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user said that they are adding more shares in the company for the “epic return to glory.”<stembedurl>https://www.stocktwits.com/McGinvests/message/643354295</stembedurl>Another user termed the selloff as “brutal” and hinted at a possible bankruptcy filing.<stembedurl>https://www.stocktwits.com/SierraIndiaDavid/message/643354859</stembedurl><a href="https://stocktwits.com/symbol/QNCX">QNCX stock</a> has lost 84% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/krro-shares-jump-on-analyst-upgrades/cmyimzWR41O">KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of InMode have fallen nearly 12% over the past 12 months. 

Why Did QNCX Stock Plummet Over 90% Today?

The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP). 

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced topline...

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases, today announced the poster...

Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Significant Growth in Short Interest

Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling...

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Quince Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $WMT earnings on Thursday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.18	--	--	N/A
Q3 '25	-$0.22	-$0.25	-16.28%	MISSED
Q2 '25	-$0.25	-$0.34	-35.10%	MISSED
Q1 '25	-$0.23	-$0.34	-49.45%	MISSED
Q4 '24	-$0.16	-$0.19	-21.28%	MISSED

QNCX
Quince Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest QNCX News

QNCXQuince Therapeutics Inc